Biodistribution of [1-¹⁴C]acetate and <i>in vivo</i> PET imaging with [1-¹¹C]acetate in tumor xenograft-bearing mice.

<p>(A) Biodistribution at 10 min and 30 min in organs (left) and each tumor (right). Data represents %ID/g, expressed as means ± SD. The groups with different alphabets are significantly different (<i>P</i><0.05). (B) Small-animal PET images of [1-¹¹C]acetate at 30 min after injection. Yellow arrows indicate tumors. S = stomach; L = liver.</p

Time-lapse analysis showing morphological changes and movement of FASN knockdown LNCaP cells.

<p>Data indicate images in control-RNAi cells (A) and FASN-RNAi 3128 cells (B). Images were taken every 6 h for 5 days. White arrowheads indicate an example of the formation of pseudopodia, spindle-shaped morphology, and active cell migration in control-RNAi cells. Black arrowheads indicate an example of the deficient formation of pseudopodia, round morphology, and low activity of cell migration in the FASN-RNAi 3128 cells.</p

Effects of FASN inhibition by RNAi in FASN-expressing LNCaP cells.

<p>FASN-RNAi 3128 and 3129 cells and control-RNAi cells were used. (A) Relative expression of FASN, analyzed by Western blotting analysis (left) and uptake of [1-¹⁴C]acetate (right). (B) Cell proliferation over 7 days (upper, left). Light microscopy images (upper, right). Relative migration and invasion potential in FASN-RNAi cells, as compared with control-RNAi cells (lower, left and right, respectively). Values from six independent experiments are shown. Data are expressed as means ± SD. The groups with different alphabets are significantly different (<i>P</i><0.05).</p

Schematic view of this study.

<p>The functions of FASN in tumors, mechanism of FASN inhibition, and method for applying [1-¹¹C]acetate PET as a predictor of outcome of FASN-targeted therapies are shown.</p